Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test.
Strongyloidiasis is a neglected tropical disease estimated to affect more than 600 million people worldwide. Recently, the World Health Organization road map on neglected tropical diseases 2021-2030 has put the focus on strongyloidiasis, including this disease within its mass drug administration cam...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-10-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://doi.org/10.1371/journal.pntd.0012532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849762102402613248 |
|---|---|
| author | María Cambra-Pellejà Elora Valderas-García Rafael Balaña-Fouce Jennifer de la Vega Esther Del Olmo Jennifer Antwi-Ekwuruke Lara Linnemann Lennart Heepmann Minka Breloer María Martínez-Valladares |
| author_facet | María Cambra-Pellejà Elora Valderas-García Rafael Balaña-Fouce Jennifer de la Vega Esther Del Olmo Jennifer Antwi-Ekwuruke Lara Linnemann Lennart Heepmann Minka Breloer María Martínez-Valladares |
| author_sort | María Cambra-Pellejà |
| collection | DOAJ |
| description | Strongyloidiasis is a neglected tropical disease estimated to affect more than 600 million people worldwide. Recently, the World Health Organization road map on neglected tropical diseases 2021-2030 has put the focus on strongyloidiasis, including this disease within its mass drug administration campaigns. With the use of ivermectin in extensive treatment of all populations at-risk, identifying effective therapeutic alternatives is crucial in case ivermectin resistance arises. The objective of the present study was the development of a larval migration inhibition assay to evaluate the anthelmintic efficacy of commercial drugs and diamine and aminoalcohol derivatives against infective Strongyloides ratti third stage larvae. Through this technique, we successfully screened and estimated the in vitro anthelmintic efficacy of six commercial drugs, seven diamine derivatives and eight aminoalcohol derivatives. Unexpectedly, the half-maximal effective concentration of ivermectin and moxidectin (2.21 and 2.34 μM, respectively) were observed as the highest value obtained among all commercial drugs tested by this in vitro technique. Moreover, some diamine and aminoalcohol derivatives showed superior efficacy inhibiting S. ratti motility compared to ivermectin, with five compounds (AA23, AA34, AO2 AO7 and AO14b) also displaying selectivity indexes on HepG2 and Caco2 higher than 1. These findings underscore the potential of these derivatives as promising alternatives for strongyloidiasis treatment, warranting further investigation and in vivo efficacy assessment. |
| format | Article |
| id | doaj-art-3aa6effc1dc14387ad41bdeda36be21d |
| institution | DOAJ |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-3aa6effc1dc14387ad41bdeda36be21d2025-08-20T03:05:50ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352024-10-011810e001253210.1371/journal.pntd.0012532Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test.María Cambra-PellejàElora Valderas-GarcíaRafael Balaña-FouceJennifer de la VegaEsther Del OlmoJennifer Antwi-EkwurukeLara LinnemannLennart HeepmannMinka BreloerMaría Martínez-ValladaresStrongyloidiasis is a neglected tropical disease estimated to affect more than 600 million people worldwide. Recently, the World Health Organization road map on neglected tropical diseases 2021-2030 has put the focus on strongyloidiasis, including this disease within its mass drug administration campaigns. With the use of ivermectin in extensive treatment of all populations at-risk, identifying effective therapeutic alternatives is crucial in case ivermectin resistance arises. The objective of the present study was the development of a larval migration inhibition assay to evaluate the anthelmintic efficacy of commercial drugs and diamine and aminoalcohol derivatives against infective Strongyloides ratti third stage larvae. Through this technique, we successfully screened and estimated the in vitro anthelmintic efficacy of six commercial drugs, seven diamine derivatives and eight aminoalcohol derivatives. Unexpectedly, the half-maximal effective concentration of ivermectin and moxidectin (2.21 and 2.34 μM, respectively) were observed as the highest value obtained among all commercial drugs tested by this in vitro technique. Moreover, some diamine and aminoalcohol derivatives showed superior efficacy inhibiting S. ratti motility compared to ivermectin, with five compounds (AA23, AA34, AO2 AO7 and AO14b) also displaying selectivity indexes on HepG2 and Caco2 higher than 1. These findings underscore the potential of these derivatives as promising alternatives for strongyloidiasis treatment, warranting further investigation and in vivo efficacy assessment.https://doi.org/10.1371/journal.pntd.0012532 |
| spellingShingle | María Cambra-Pellejà Elora Valderas-García Rafael Balaña-Fouce Jennifer de la Vega Esther Del Olmo Jennifer Antwi-Ekwuruke Lara Linnemann Lennart Heepmann Minka Breloer María Martínez-Valladares Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. PLoS Neglected Tropical Diseases |
| title | Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. |
| title_full | Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. |
| title_fullStr | Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. |
| title_full_unstemmed | Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. |
| title_short | Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. |
| title_sort | evaluating alternative compounds for strongyloidiasis therapy novel insights from larval migration inhibition test |
| url | https://doi.org/10.1371/journal.pntd.0012532 |
| work_keys_str_mv | AT mariacambrapelleja evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT eloravalderasgarcia evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT rafaelbalanafouce evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT jenniferdelavega evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT estherdelolmo evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT jenniferantwiekwuruke evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT laralinnemann evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT lennartheepmann evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT minkabreloer evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest AT mariamartinezvalladares evaluatingalternativecompoundsforstrongyloidiasistherapynovelinsightsfromlarvalmigrationinhibitiontest |